Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Ludwig

Showing results (291-300 of 307) with videos related to

Pageof 31
Sort By:
Journal for Immunotherapy of Cancer|June 6, 2018
Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054Yiwen Li, Carmine Carpenito, George Wang, et al.
Biochemical and Biophysical Research Communications|April 28, 2007
An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibodyJuqun Shen, Marie D Vil, Haifan Zhang, et al.
American Journal of Veterinary Research|June 26, 2015
Comparison of two- and three-times-daily topical ophthalmic application of 0.005% latanoprost solution in clinically normal dogsKyle L Tofflemire, Elizabeth M Whitley, Rachel A Allbaugh, et al.
Cancer Research|September 20, 2006
Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family memberJennifer M O'Toole, Karen E Rabenau, Kerri Burns, et al.
Mabs|June 16, 2015
A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradationYang Shen, Lin Zeng, Ruslan Novosyadlyy, et al.
Cell Reports. Medicine|April 21, 2026
Plasma extracellular vesicle proteomics nominates candidate biomarkers of <sup>177</sup>Lu-PSMA-617 outcomes in metastatic prostate cancer patientsAli T Arafa, Ella Boytim, Megan L Ludwig, et al.
JAMA Otolaryngology-- Head & Neck Surgery|April 15, 2016
Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell CarcinomaAndrew C Birkeland, Megan Yanik, Brittny N Tillman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cellsZhaojing Zhong, Kyla Driscoll Carroll, Desiree Policarpio, et al.
Molecular Cancer Therapeutics|April 4, 2020
Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor ImmunityHelen Kotanides, Rose Marie Sattler, Maria B Lebron, et al.
Nature Communications|January 15, 2021
Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapyMylène Tajan, Marc Hennequart, Eric C Cheung, et al.
Pageof 31

Showing results (291-300 of 307) with videos related to

Sort By:
Pageof 31
Journal for Immunotherapy of Cancer|June 6, 2018
Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054Yiwen Li, Carmine Carpenito, George Wang, et al.
Biochemical and Biophysical Research Communications|April 28, 2007
An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibodyJuqun Shen, Marie D Vil, Haifan Zhang, et al.
American Journal of Veterinary Research|June 26, 2015
Comparison of two- and three-times-daily topical ophthalmic application of 0.005% latanoprost solution in clinically normal dogsKyle L Tofflemire, Elizabeth M Whitley, Rachel A Allbaugh, et al.
Cancer Research|September 20, 2006
Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family memberJennifer M O'Toole, Karen E Rabenau, Kerri Burns, et al.
Mabs|June 16, 2015
A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradationYang Shen, Lin Zeng, Ruslan Novosyadlyy, et al.
Cell Reports. Medicine|April 21, 2026
Plasma extracellular vesicle proteomics nominates candidate biomarkers of <sup>177</sup>Lu-PSMA-617 outcomes in metastatic prostate cancer patientsAli T Arafa, Ella Boytim, Megan L Ludwig, et al.
JAMA Otolaryngology-- Head & Neck Surgery|April 15, 2016
Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell CarcinomaAndrew C Birkeland, Megan Yanik, Brittny N Tillman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cellsZhaojing Zhong, Kyla Driscoll Carroll, Desiree Policarpio, et al.
Molecular Cancer Therapeutics|April 4, 2020
Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor ImmunityHelen Kotanides, Rose Marie Sattler, Maria B Lebron, et al.
Nature Communications|January 15, 2021
Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapyMylène Tajan, Marc Hennequart, Eric C Cheung, et al.
Pageof 31